A year ago, Johnson & Johnson was harshly criticized for declining to join Medicines Patent Pool, which is an initiative designed to streamline patent licensing for producing generics of patented HIV meds and offering lower prices in poor countries. ...
[Published Pharmalot - Nov 29 2012]